FDA-Approved MedicationUpdated November 2026

Zepbound Guide

Zepbound is the brand-name formulation of tirzepatide 2.5–15mg that Eli Lilly launched in late 2023 for long-term weight management. In 2024 its label gained a second use: treating moderate to severe obstructive sleep apnea when an adult also has obesity. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

At a Glance

Zepbound at a glance
Generic NameTirzepatide
Brand NamesZepbound
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (November 2023), and in adults with obesity, for moderate to severe obstructive sleep apnea (December 2024)[1]
Approval DateNovember 8, 2023[1]

How does Zepbound work?

Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]

Dosing Schedule

Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (maintenance)

What side effects does Zepbound cause?

Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models. The suicidal behavior and ideation section was removed from the label in February 2026.[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 20.9% over 72 weeks. The lower doses ran 19.5% at 10mg and 15.0% at 5mg, against 3.1% on placebo. Against the 5%-of-body-weight bar, the 15mg dose put 91% of participants over it.[2][3]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where can you get Zepbound?

Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.

8.8/ 10
Verified partner

altRX

Best for: compounded semaglutide from $89/month at the same price at every dose

★★★★☆8.8/10

Editorial score · methodology

$1,249/mo
BrandTirzepatideLegitScript Verified
Get StartedRead full altRX review →
8.1/ 10
Verified partner

Sesame Care

Best for: oral orforglipron alongside the injectables

★★★★☆8.1/10

Editorial score · methodology

$299/mo+ care fee
BrandTirzepatide
Get StartedRead full Sesame Care review →
7.9/ 10
Verified partner

RxSpan MD

Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy

★★★★☆7.9/10

Editorial score · methodology

$1,069/mo
BrandTirzepatideGlutathioneNAD+SermorelinLegitScript Verified
Get StartedRead full RxSpan MD review →
7.9/ 10
Verified partner

Luvo Health

Best for: moving between compounded and brand without changing seller

★★★★☆7.9/10

Editorial score · methodology

$1,399/mo
BrandTirzepatideGonadorelinNAD+SermorelinLegitScript Verified
Get StartedRead full Luvo Health review →
7.9/ 10
Verified partner

ShedRx

Best for: oral orforglipron alongside the injectables

★★★★☆7.9/10

Editorial score · methodology

$299/mo+ membership
BrandTirzepatideGHK-CuGlutathioneNAD+
Get StartedRead full ShedRx review →
7.4/ 10
Verified partner

Wellorithm

Best for: compounded semaglutide at a flat $247 every 28 days, any dose

★★★★☆7.4/10

Editorial score · methodology

$1,199/moprepaid
BrandTirzepatide
Get StartedRead full Wellorithm review →

66 sellers in the register publish a price; the lowest starts at $299 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded tirzepatide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[4], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Starting Zepbound price per seller, cheapest first. Prices in USD per month; checked November 2026.
ProviderStarting PriceLink
Amazon One Medical$299/moVisit
Aspire Health$299/mo + care feeVisit
Found$299/mo + membershipVisit
GoodRx$299/moVisit
Heally$299/moVisit
Healthspan$299/mo + membershipVisit
Hims$299/mo + membershipVisit
Imbue Health$299/mo + membershipVisit
Intermountain Health On-Demand Weight Loss$299/mo + consult feeVisit
Klinic$299/moVisit
Show all 66 Zepbound sellers
Zepbound sellers 11 to 66, cheapest first. Prices in USD per month.
Knownwell$299/mo + visit feeVisit
LillyDirect$299/moVisit
médetone$299/mo + membershipVisit
Mochi Health$299/mo + membershipVisit
PreventiveMD$299/moVisit
Ro$299/mo + membershipVisit
Sculpt Rx$299/mo + membershipVisit
Sesame Care$299/mo + care feeVisit
ShedRx$299/mo + membershipVisit
Walgreens Weight Management$299/mo + visit feeVisit
WeightWatchers Clinic$299/mo + membershipVisit
ZipHealth$299/mo + feesVisit
Noom$349/moVisit
GOAL.MD$394/moVisit
Alloy$398/moVisit
Phoenix NP$403/moVisit
Navio MD$445/moVisit
LifeMD$448/moVisit
Maximus$449.99/moVisit
Immortals$600/mo, prepaidVisit
WePeptideRx$699/moVisit
Pallas Health$1,069/moVisit
RxSpan MD$1,069/moVisit
Josie$1,099/moVisit
Wellorithm$1,199/mo, prepaidVisit
altRX$1,249/moVisit
Wellya$1,249/moVisit
RxION Health$1,259/moVisit
Elevate Health$1,289/moVisit
NoBsRx$1,299/moVisit
Astra$1,300/moVisit
DudeMeds$1,350/moVisit
Oak$1,350/moVisit
HeliMeds$1,396/mo, prepaidVisit
Aquivia Health$1,399/moVisit
GobyMeds$1,399/moVisit
Luvo Health$1,399/moVisit
Peptivo$1,399/moVisit
Remmy$1,399/moVisit
Tomorrow$1,399/moVisit
TrimRx$1,399/moVisit
Tryozi$1,399/moVisit
Vytora Health$1,399/moVisit
XMD Wellness$1,399/moVisit
Effecty$1,400/moVisit
Elara Women's Wellness$1,400/moVisit
SkinnyRx$1,400/moVisit
OrderlyMeds$1,498/moVisit
BiltRx$1,499/moVisit
Corsica Health$1,499/moVisit
WellMedRx$1,599/moVisit
Good Girl Rx$1,688/moVisit
Layla$1,699/moVisit
Fridays$1,828/moVisit
Nucific$1,828/moVisit
NuuVim$1,892/moVisit

Short verdict pages setting Zepbound against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

The trials that produced the Zepbound label, taken endpoint by endpoint, with the figures read off the source.

SURMOUNT-1
SURMOUNT-1 put tirzepatide at 5, 10 and 15 mg weekly against placebo in 2,539 adults who had obesity, or excess weight plus a related complication. The top dose reached -20.9% body weight at 72 weeks against -3.1% on placebo. No approved weight drug had achieved more in a phase 3 trial, and the result became the evidence behind Zepbound's approval. It also reset what the whole market claims it can deliver, including products carrying no trial evidence whatsoever.
Phase 3 · N=2,539
SURMOUNT-OSA
SURMOUNT-OSA tested tirzepatide in 469 people carrying obesity alongside moderate-to-severe obstructive sleep apnea, split into two cohorts: those using positive airway pressure and those not. The apnea-hypopnea index fell 25.3 events an hour without PAP and 29.3 with it, against roughly 5 on placebo. It produced a second FDA indication for Zepbound and turned a weight-management drug into a treatment for a specific, diagnosable condition.
Phase 3 · N=469
SURMOUNT-2
SURMOUNT-2 ran tirzepatide in the population SURMOUNT-1 excluded: adults with type 2 diabetes as well as obesity. At 15 mg the result was −14.7% body weight at 72 weeks against −3.2% on placebo. That is a substantial effect, and it is six percentage points below what the same drug produced in people without diabetes. For anyone with diabetes reading marketing built on SURMOUNT-1, that gap is the most useful comparison available.
Phase 3 · N=938
SURMOUNT-3
SURMOUNT-3 answered a question the other trials skip: what does the drug add for someone who has already succeeded with lifestyle change? All 579 participants completed a 12-week intensive lifestyle lead-in first. Those randomized to tirzepatide then lost a further 18.4%; those on placebo regained 2.5%. The design isolates the drug's contribution on top of behavioral success rather than instead of it.
Phase 3 · N=579

Questions people actually asked about Zepbound in named subreddits, each answered from the published trial data.

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

The peer-reviewed studies on Zepbound and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
A 503A pharmacy compounds per patient under a state board. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected and must report adverse events. What each means for compounded GLP-1s, and how to check yours.
10 min read12 citations
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read3 citations
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
5 min read3 citations
Tirzepatide vs Dulaglutide: A Real Head-to-Head
13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.
6 min read1 citation
Does Your GLP-1 Wear Off Before the Next Dose?
Half of each dose is still present when the next one is due. The label puts semaglutide's elimination half-life at roughly seven days, tirzepatide's at about five. That is a slope, not a cliff.
6 min read2 citations
GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.
7 min read9 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (November 2023), and in adults with obesity, for moderate to severe obstructive sleep apnea (December 2024)
What you pay for Zepbound turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models. The suicidal behavior and ideation section was removed from the label in February 2026.
Zepbound is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of November 2026
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.